Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3965 |
Name | Merkel cell carcinoma |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer integumentary system cancer skin cancer skin carcinoma Merkel cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 wild-type | ALRN-6924 | Merkel cell carcinoma | predicted - sensitive | detail... |
RB1 loss | LY3295668 | Merkel cell carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02036476 | Phase II | Cabozantinib | Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma | Terminated | USA | 0 |
NCT02155647 | Phase II | Avelumab | Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200) | Completed | USA | ITA | FRA | ESP | DEU | AUS | 1 |
NCT02267603 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer | Completed | USA | 0 |
NCT02488759 | Phase Ib/II | Nivolumab | A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) | Completed | USA | NLD | GBR | FRA | ESP | DEU | BEL | 4 |
NCT02514824 | Phase Ib/II | Sapanisertib | MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma | Completed | USA | 0 |
NCT02584829 | Phase Ib/II | IFN-B Avelumab | Localized Radiation Therapy or Recombinant Interferon Beta and MSB0010718C With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma | Terminated | USA | 0 |
NCT02643303 | Phase Ib/II | Durvalumab + Poly ICLC Tremelimumab | A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers | Completed | USA | 0 |
NCT02819843 | Phase II | Talimogene laherparepvec | A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors | Completed | USA | 0 |
NCT02831179 | Phase I | Capecitabine + Temozolomide + Veliparib | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | Withdrawn | 0 | |
NCT02936323 | Phase Ib/II | PEN-221 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | Completed | USA | GBR | 0 |
NCT02978625 | Phase II | Nivolumab + Talimogene laherparepvec | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | Active, not recruiting | USA | 0 |
NCT03071406 | Phase II | Ipilimumab + Nivolumab | Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03074513 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | Active, not recruiting | USA | 0 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Active, not recruiting | POL | NZL | FRA | ESP | AUS | 4 |
NCT03228667 | Phase II | Docetaxel + Nivolumab + Nogapendekin alfa inbakicept Docetaxel + Nogapendekin alfa inbakicept + Pembrolizumab Nivolumab + Nogapendekin alfa inbakicept Nogapendekin alfa inbakicept + Pembrolizumab Durvalumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Avelumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Atezolizumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Nivolumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Durvalumab + Nogapendekin alfa inbakicept Nogapendekin alfa inbakicept + PD-L1.t-haNK cells + Pembrolizumab Avelumab + Nogapendekin alfa inbakicept Atezolizumab + Nogapendekin alfa inbakicept | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | Recruiting | USA | 0 |
NCT03271372 | Phase III | Avelumab | Adjuvant Avelumab in Merkel Cell Cancer (ADAM) | Active, not recruiting | USA | 0 |
NCT03304639 | Phase II | Pembrolizumab | Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer | Active, not recruiting | USA | 0 |
NCT03416335 | Phase Ib/II | DSP-0509 DSP-0509 + Pembrolizumab | A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile | Terminated | USA | 0 |
NCT03435640 | Phase Ib/II | NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 | A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies | Terminated | USA | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03590054 | Phase I | Abexinostat + Pembrolizumab | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | Completed | USA | 0 |
NCT03599713 | Phase II | Retifanlimab | A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma | Completed | USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | AUS | 0 |
NCT03628677 | Phase I | AB154 AB154 + Zimberelimab | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Completed | USA | AUS | 0 |
NCT03629756 | Phase I | Etrumadenant + Zimberelimab | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Completed | USA | AUS | 0 |
NCT03712605 | Phase III | Pembrolizumab | Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer | Active, not recruiting | USA | 0 |
NCT03747484 | Phase Ib/II | Avelumab + FH-MCVA2TCR | Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer | Terminated | USA | 0 |
NCT03767348 | Phase Ib/II | Nivolumab + RP1 RP1 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) | Recruiting | USA | GBR | FRA | ESP | DEU | 0 |
NCT03783078 | Phase III | Pembrolizumab | Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) | Completed | USA | SWE | NZL | ITA | FRA | ESP | CAN | AUS | 0 |
NCT03787602 | Phase Ib/II | Avelumab + KRT-232 KRT-232 | Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | Recruiting | USA | NLD | ITA | FRA | ESP | DEU | CAN | BRA | AUS | 1 |
NCT03798639 | Phase I | Ipilimumab + Nivolumab Nivolumab | Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer | Completed | USA | 0 |
NCT03816332 | Phase I | Ipilimumab + Nivolumab + Prednisone + Tacrolimus | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | Active, not recruiting | USA | 0 |
NCT03816345 | Phase I | Nivolumab | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Recruiting | USA | CAN | 0 |
NCT03853317 | Phase II | Avelumab + haNK cells + Nogapendekin alfa inbakicept | Evaluate Efficacy of Avelumab, haNK and N-803 in Subjects With Progressed MCC on or After Checkpoint Inhibitor Therapy. | Terminated | USA | 0 |
NCT03901573 | Phase Ib/II | Atezolizumab + NT-I7 | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | Terminated | USA | 0 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Terminated | USA | FRA | BEL | AUS | 1 |
NCT03988647 | Phase II | Pembrolizumab | Phase II Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma | Terminated | USA | 0 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04160065 | Phase I | IFx-Hu2.0 | Immunotherapy With IFx-Hu2.0 Vaccine for Advanced MCC or cSCC | Completed | USA | 0 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04261855 | Phase Ib/II | Avelumab Avelumab + lutetium Lu 177 dotatate | Targeted Therapy and Avelumab in Merkel Cell Carcinoma (GoTHAM) | Recruiting | AUS | 0 |
NCT04291885 | Phase II | Avelumab | Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma (I-MAT) | Active, not recruiting | NZL | AUS | 0 |
NCT04349436 | Phase Ib/II | RP1 | A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies (ARTACUS) | Recruiting | USA | 0 |
NCT04393753 | Phase II | Avelumab + Domatinostat | Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 (MERKLIN2) | Completed | NLD | ITA | FRA | ESP | DEU | BEL | 0 |
NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04590781 | Phase Ib/II | Pembrolizumab + XmAb18087 XmAb18087 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | Terminated | USA | 0 |
NCT04725331 | Phase Ib/II | BT-001 BT-001 + Pembrolizumab | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | Recruiting | FRA | BEL | 0 |
NCT04787042 | Phase Ib/II | Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Recruiting | USA | 0 |
NCT04792073 | Phase II | Avelumab | Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma | Recruiting | USA | 0 |
NCT04819373 | Phase II | EIK1001 | BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors | Completed | USA | 0 |
NCT04869137 | Phase II | Lenvatinib + Pembrolizumab | Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT04874831 | Phase II | Avelumab + Domatinostat | Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1) | Withdrawn | 0 | |
NCT04902040 | Phase Ib/II | Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab + Plinabulin Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | Terminated | USA | 0 |
NCT04902443 | Phase I | Nivolumab + Pomalidomide | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | Recruiting | USA | 0 |
NCT04916002 | Phase II | Cemiplimab + Vidutolimod | CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer | Terminated | USA | AUS | 0 |
NCT04975152 | Phase I | Cemiplimab | Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT05076760 | Phase I | MEM-288 | Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | 0 |
NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | CAN | AUS | 1 |
NCT05120271 | Phase Ib/II | BOXR1030 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1) | Recruiting | USA | GBR | 0 |
NCT05199272 | Phase Ib/II | 23ME-00610 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | Active, not recruiting | USA | CAN | 0 |
NCT05269381 | Phase I | Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) | Recruiting | USA | 0 |
NCT05329792 | Phase II | Daromun | L19IL2/L19TNF in Skin Cancer Patients | Recruiting | ITA | FRA | ESP | 0 |
NCT05422781 | Phase I | ITI-3000 | Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC) | Completed | USA | 0 |
NCT05496036 | Phase II | Pembrolizumab | Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma (MCC) | Recruiting | USA | 0 |
NCT05583708 | Phase II | lutetium Lu 177 dotatate + Pembrolizumab | Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer (iPRRT) | Suspended | USA | 0 |
NCT05594290 | Phase II | Cisplatin + Etoposide + Retifanlimab | Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery (MERCURY) | Recruiting | ITA | 0 |
NCT05859074 | Phase I | MQ710 + Pembrolizumab MQ710 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | Active, not recruiting | USA | 0 |
NCT05896839 | Phase Ib/II | Ipilimumab + Nivolumab + Prednisone + Sirolimus | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | Recruiting | USA | 0 |
NCT05904496 | Phase I | BGB-30813 BGB-30813 + Tislelizumab | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ESP | AUS | 0 |
NCT05947500 | Phase II | M1774 Avelumab + M1774 | Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial | Recruiting | USA | CAN | 0 |
NCT06014086 | Phase I | PH-762 | Intratumoral PH-762 for Cutaneous Carcinoma | Recruiting | USA | 0 |
NCT06021626 | Phase I | CRD3874 | A Study of CRD3874-SI in People With Sarcoma or Merkel Cell Cancer | Recruiting | USA | 0 |
NCT06047379 | Phase Ib/II | NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Recruiting | USA | 0 |
NCT06056895 | Phase II | INCAGN02385 + INCAGN02390 + Retifanlimab | Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma (TRICK-MCC) | Active, not recruiting | USA | 0 |
NCT06086288 | Phase II | Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab | Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naive Advanced meRkel Cell cArcinoma (MCC) (PANDORA) | Not yet recruiting | ITA | 0 |
NCT06151236 | Phase II | Nivolumab + Relatlimab | Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma | Recruiting | AUS | 0 |
NCT06514651 | Phase I | MAQ-001 Ipilimumab + MAQ-001 | MAQ-001 in Patients With Advanced Solid Tumors | Recruiting | FRA | 0 |
NCT06814496 | Phase Ib/II | Tarlatamab | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) | Not yet recruiting | USA | 0 |